Last reviewed · How we verify

Emdogain (EMD) - test — Competitive Intelligence Brief

Emdogain (EMD) - test (Emdogain (EMD) - test) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Regenerative biologic / Enamel matrix derivative. Area: Dentistry / Periodontics.

marketed Regenerative biologic / Enamel matrix derivative Enamel matrix proteins (EMPs); indirect effects on growth factors and cell signaling pathways Dentistry / Periodontics Biologic Live · refreshed every 30 min

Target snapshot

Emdogain (EMD) - test (Emdogain (EMD) - test) — Universidad Complutense de Madrid. Emdogain is a protein extract derived from developing tooth buds that promotes periodontal regeneration by stimulating growth factors and extracellular matrix formation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Emdogain (EMD) - test TARGET Emdogain (EMD) - test Universidad Complutense de Madrid marketed Regenerative biologic / Enamel matrix derivative Enamel matrix proteins (EMPs); indirect effects on growth factors and cell signaling pathways

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Regenerative biologic / Enamel matrix derivative class)

  1. Universidad Complutense de Madrid · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Emdogain (EMD) - test — Competitive Intelligence Brief. https://druglandscape.com/ci/emdogain-emd-test. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: